Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. YI
YI logo

YI Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
7.209
Open
6.810
VWAP
6.99
Vol
9.53K
Mkt Cap
92.95M
Low
6.810
Amount
66.57K
EV/EBITDA(TTM)
581.88
Total Shares
--
EV
170.00M
EV/OCF(TTM)
4.65
P/S(TTM)
0.03
111 Inc is an investment holding company primarily engaged in the operation of integrated online and offline healthcare platform. The Company mainly operates its business through two segments. The Business to Customer (B2C) segment is engaged in the sale of pharmaceutical and other health and wellness products through 1 Medicine Marketplace, mobile apps, other online channels and offline pharmacies to consumers and certain enterprise customers. The Business to Business (B2B) segment is engaged in the sale of pharmaceutical products to pharmacies on 1 Pharmacy. The Company also provides customers with online consultation and electronic prescription services through the Internet hospital 1 Clinic. The Company’s products include drugs, nutritional supplements, medical supplies and devices and other products. The Company mainly conducts its business in the domestic market.
Show More

Events Timeline

(ET)
2026-01-30
14:50:00
111 Inc ADR Trading Halted Due to Volatility Trading Pause
select
2025-02-11 (ET)
2025-02-11
07:01:56
111, Inc. regains Nasdaq compliance
select
2025-01-08 (ET)
2025-01-08
04:08:32
111, Inc. announces one-for-twenty ADS ratio change
select
2024-10-10 (ET)
2024-10-10
06:12:51
111, Inc. announces South, Central China fulfillment centers begin operations
select
2024-09-27 (ET)
2024-09-27
17:28:47
111, Inc. discloses Nasdaq listing deficiency notice
select
2024-08-29 (ET)
2024-08-29
05:17:09
111, Inc. reports Q2 EPS (RMB 0.16) vs. (RMB 0.68) last year
select

News

PRnewswire
9.5
2025-12-17PRnewswire
111, Inc. Achieves Non-GAAP Profitability for Third Consecutive Quarter
  • Financial Performance: 111, Inc. reported net revenues of RMB 3.0 billion (approximately $421.5 million) for Q3 2025, reflecting a 16.7% year-over-year decline, yet achieved non-GAAP operational profitability for the third consecutive quarter amidst macroeconomic challenges.
  • Strategic Shift: The company divested 100% equity interests in three self-operated subsidiaries, which may temporarily impact revenue but strengthens liquidity and profitability by transitioning to an asset-light model, enhancing long-term financial health.
  • Supply Chain Optimization: Through the ongoing 'MANTIANXING' initiative, the fulfillment center network has expanded, generating RMB 498 million in inventory value, driving 20.5% GMV growth and 31.0% increase in customer count, significantly enhancing overall competitiveness.
  • Future Outlook: 111, Inc. aims to build an AI-powered pharmaceutical procurement transaction platform, leveraging AI to optimize decision-making and enhance customer experience, which is expected to unlock long-term value for shareholders.
Newsfilter
2.0
2025-12-17Newsfilter
111, Inc. Transitions to Asset-Light Model, Achieves Non-GAAP Profitability for Three Consecutive Quarters
  • Financial Performance: 111, Inc. reported third-quarter net revenues of RMB 3.0 billion (approximately $421.5 million), a 16.7% year-over-year decline, yet achieved non-GAAP net income of RMB 1.1 million (about $0.2 million), demonstrating resilience in profitability amidst market challenges.
  • Cost Control: Operating expenses decreased to RMB 180.3 million (approximately $25.3 million), down 13.4% from the previous year, reflecting effective structural optimization and a shift to an asset-light model that enhances liquidity and profitability.
  • Strategic Transition: The company divested three self-operated subsidiaries, moving towards an asset-light partnership network, which is expected to improve operational efficiency and reduce capital burdens, thereby supporting future high-margin growth.
  • Supply Chain Optimization: The
PRnewswire
9.5
2025-09-17PRnewswire
111, Inc. Announces Second Quarter 2025 Unaudited Financial Results
  • Financial Performance: 111, Inc. reported a net revenue of RMB 3.2 billion for Q2 2025, a 6.4% decrease year-over-year, while maintaining operational profitability and positive cash flow, with operating expenses reduced by 9.3% compared to the previous year.

  • Strategic Initiatives: The company is focusing on enhancing its supply chain capabilities and digital marketing efforts, achieving a 53.6% increase in sales revenue from marketing promotional products and expanding fulfillment centers to 19 locations nationwide.

Yahoo Finance
9.5
2025-06-19Yahoo Finance
111, Inc. Announces First Quarter 2025 Unaudited Financial Results
  • Financial Performance: 111, Inc. reported stable net revenues of RMB 3.5 billion for Q1 2025, with a slight year-over-year decrease in income from operations and a net loss of RMB 7.3 million, while maintaining positive operating cash flow and reducing operating expenses as a percentage of revenues.

  • Operational Efficiency: The company achieved a 4.8% reduction in total operating expenses compared to the previous year, highlighting improvements in operational efficiency driven by cost management strategies, particularly in selling, marketing, and technology expenses.

NASDAQ.COM
9.5
2025-06-19NASDAQ.COM
111 Q1 Loss Widens, Net Revenues Flat
  • Financial Performance: 111, Inc. reported a wider net loss of RMB17.65 million in Q1 due to increased expenses, with nearly flat net revenues of RMB3.529 billion, reflecting only a 0.02% increase from the previous year.

  • Future Strategy: CEO Junling Liu emphasized the company's focus on leveraging technology and investing in AI and digital solutions to enhance their healthcare supply chain and customer engagement.

PRnewswire
9.5
2025-03-20PRnewswire
111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results
  • Financial Performance: 111, Inc. reported its first-ever annual operating profit of RMB2.1 million in 2024, alongside a positive operating cash flow of RMB263 million, despite facing a challenging macroeconomic environment that led to a decrease in net revenues and gross segment profit year-over-year.

  • Operational Efficiency: The company improved its operational efficiency significantly, with total operating expenses as a percentage of revenues decreasing by 230 basis points to 5.7% for the fiscal year, while also achieving notable reductions in various expense categories, including selling and marketing costs.

Valuation Metrics

The current forward P/E ratio for 111 Inc (YI.O) is 0.00, compared to its 5-year average forward P/E of 10.82. For a more detailed relative valuation and DCF analysis to assess 111 Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
10.82
Current PE
0.00
Overvalued PE
59.87
Undervalued PE
-38.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.79
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
24.07
Undervalued EV/EBITDA
-22.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.11
Current PS
0.04
Overvalued PS
0.21
Undervalued PS
-0.00

Financials

AI Analysis
Annual
Quarterly

Whales Holding YI

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is 111 Inc (YI) stock price today?

The current price of YI is 6.941 USD — it has decreased -0.27

What is 111 Inc (YI)'s business?

111 Inc is an investment holding company primarily engaged in the operation of integrated online and offline healthcare platform. The Company mainly operates its business through two segments. The Business to Customer (B2C) segment is engaged in the sale of pharmaceutical and other health and wellness products through 1 Medicine Marketplace, mobile apps, other online channels and offline pharmacies to consumers and certain enterprise customers. The Business to Business (B2B) segment is engaged in the sale of pharmaceutical products to pharmacies on 1 Pharmacy. The Company also provides customers with online consultation and electronic prescription services through the Internet hospital 1 Clinic. The Company’s products include drugs, nutritional supplements, medical supplies and devices and other products. The Company mainly conducts its business in the domestic market.

What is the price predicton of YI Stock?

Wall Street analysts forecast YI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for YI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is 111 Inc (YI)'s revenue for the last quarter?

111 Inc revenue for the last quarter amounts to 3.85B USD, decreased -6.35

What is 111 Inc (YI)'s earnings per share (EPS) for the last quarter?

111 Inc. EPS for the last quarter amounts to -1.15 USD, decreased -90.71

How many employees does 111 Inc (YI). have?

111 Inc (YI) has 1238 emplpoyees as of March 10 2026.

What is 111 Inc (YI) market cap?

Today YI has the market capitalization of 92.95M USD.